Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week’s View, Dr. Eagle explores the disparities in diagnosis, treatment, and outcomes of peripheral artery disease. He then discusses evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy. Finally, Dr. Eagle examines the importance of residual leaks following percutaneous left atrial appendage occlusion and outcomes.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores longitudinal changes in pulmonary artery pressure late in life using data from the ARIC study. He then discusses the safety and tolerability of inclisiran for treatment of hypercholesterolemia. Finally, Dr. Eagle asses late gadolinium enhancement in hypertrophic cardiomyopathy and how it improves risk stratification based on current guidelines.  Subscribe to Eagle’s Eye View  

The podcast explores stroke and bleeding risk in patients with atrial fibrillation and a CHA2DS2-VASC risk score of 1. It discusses the key points in the recently released 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. The potential value of using high-sensitivity cardiac troponin as a biomarker to predict preeclampsia is also examined.

In this week’s View, Dr. Eagle explores a meta-analysis of direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation. He then discusses a 20-year study of sudden cardiac death in National Collegiate Athletic Association athletes. Finally, Dr. Eagle examines the cardiovascular effects of novel weight loss therapies.  Subscribe to Eagle’s Eye View  

The podcast discusses the role of inflammation in predicting coronary risk and provides insights for clinical practice. It also explores the effects of renal denervation on blood pressure in patients with resistant hypertension.

Cardiologists and researchers Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane discuss late-breaking science from the American Heart Association Scientific Sessions 2023, covering topics such as blood pressure targets, transfusion strategies for anemic heart attack patients, complete revascularization, risk stratification, and an AI-based approach to assess fat attenuation as a risk marker in cardiology.

Guests Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane discuss late-breaking clinical trials from the American Heart Association Scientific Sessions. Topics include the safety and efficacy of a novel agent called Abecidimap, concerns about a new antibody mechanism for lenticoagulation, and the use of digital technology in gathering information about acrofibulation and reducing heart disease risk in HIV patients.

Experts review late-breaking clinical trials at AHA 2023, including semaglutide's benefits in obese patients with cardiovascular disease, the cardiometabolic effects of DAPA in acute MI patients, and the effectiveness of PCI vs. medical therapy in patients with angina.

This podcast explores the impact of residual ischemia on cardiovascular mortality in left main bifurcation stenting. It also discusses the comparison between instantaneous wave free ratio and fractional flow reserve, as well as the discontinuation of tycagrelor after percutaneous coronary intervention.

In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at AHA 2023 from November 11 to November 13 in Philadelphia.    Dr. Eagle shares some of the trials that have captured attention, including:  SELECT, that investigates semaglutide and cardiovascular outcomes in non-diabetic patients who are overweight or obese;  ORBITA-2, a randomized trial that evaluates PCI for Stable Angina; DAPA-MI, a registry-based randomized trial examining the effects of Dapagliflozin in patients with acute myocardial infarction without diabetes; the REPRIEVE study that investigates the effects of pitavastatin on coronary artery disease and inflammatory biomarkers in individuals with HIV; the HEART-1 trial that discusses the safety and pharmacodynamic effects of VERVE-101, an investigational DNA base editing medicine; and the ESPIRIT trial investigating the effects of intensive blood pressure lowering treatment in reducing the risk of cardiovascular events. These trials hold significant promise for advancing the field of cardiology.  Our team looks forward to reviewing the results at AHA 2023.    There will be daily updates giving more details on these trials and more.  Subscribe to Eagle’s Eye View